Granted Patent
B2
US 12,612,464 · App. 17/642,773 · Granted Apr 28, 2026
Autoantibody specifically binding to NELL-1 and elevated NELL-1 polypeptide levels for identifying and treating membranous nephropathy
Inventors:
Sanjeev Sethi (Rochester, MN); Fernando C. Fervenza (Rochester, MN); Benjamin J. Madden (Stewartville, MN); M. Cristine Charlesworth (Rochester, MN)
C07K16/2887A61K31/196A61K31/436A61K38/13A61P37/06G01N33/564A61K39/00C07K2317/24G01N2800/347G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a neural epidermal growth factor (EGF)-like 1 (NELL-1) polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more immunosuppressive agents (e.g., corticosteroids, cyclosporine, or a B-cell reduction or depletion agent such as Rituximab) to treat a mammal (e.g., a human) having membranous nephropathy are provided.
Claims (17)
1 . A method for treating membranous nephropathy, wherein said method comprises administering an immunosuppressant to a mammal identified as having membranous nephropathy and (i) autoantibodies specific for a polypeptide or (ii) kidney tissue comprising an elevated level of said polypeptide, wherein said polypeptide is a neural epidermal growth factor (EGF)-like 1 (NELL-1) polypeptide.
2 . The method of claim 1 , wherein said mammal is a human.
3 . The method of claim 1 , wherein said immunosuppressant is selected from the group consisting of a B-cell inhibitor, a calcineurin inhibitor, an mTOR inhibitor, and a DNA damage inducer.
4 . The method of claim 3 , wherein said B-cell inhibitor is rituximab.
5 . The method of claim 3 , wherein said calcineurin inhibitor is cyclosporine or tacrolimus.
6 . The method of claim 3 , wherein said mTOR inhibitor is sirolimus or everolimus.
7 . The method of claim 3 , wherein said DNA damage inducer is chlorambucil.
8 . The method of claim 1 , wherein the level of autoantibodies present within said mammal is reduced by at least 5 percent following said administering step.
9 . A method for detecting (i) a presence or absence of autoantibodies specific for a polypeptide or (ii) a presence or absence of kidney tissue comprising an elevated level of said polypeptide in a sample of said kidney tissue from said mammal, wherein said polypeptide is a neural epidermal growth factor (EGF)-like 1 (NELL-1) polypeptide, in a sample of a mammal having or suspected of having membranous nephropathy.
10 . The method of claim 9 , wherein said mammal is a human.
11 . The method of claim 9 , wherein said mammal has the presence of said autoantibodies or the presence of said kidney tissue comprising the elevated level of said polypeptide, and said method comprises administering an immunosuppressant to said mammal.
12 . The method of claim 11 , wherein said immunosuppressant is selected from the group consisting of a B-cell inhibitor, a calcineurin inhibitor, an mTOR inhibitor, and a DNA damage inducer.
13 . The method of claim 12 , wherein said B-cell inhibitor is rituximab.
14 . The method of claim 12 , wherein said calcineurin inhibitor is cyclosporine or tacrolimus.
15 . The method of claim 12 , wherein said mTOR inhibitor is sirolimus or everolimus.
16 . The method of claim 12 , wherein said DNA damage inducer is chlorambucil.
17 . The method of claim 11 , wherein the level of autoantibodies present within said mammal is reduced by at least 5 percent following said administering step.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 29, 2022
From: SETHI, SANJEEV; FERVENZA, FERNANDO C.; MADDEN, BENJAMIN J.; CHARLESWORTH, M. CRISTINE
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 059769/0950 →
Continuity (2)
Provisional Application
62902821
· Sep 19, 2019
References Cited (115)
US 8361721B2
· Copland et al.
· 2013
[cited by applicant]
US 20060040293A1
· Salonen et al.
· 2006
[cited by applicant]
US 20080081333A1
· Mori
· 2008
[cited by examiner]
US 20100167285A1
· Schreiber et al.
· 2010
[cited by applicant]
US 20100196426A1
· Skog et al.
· 2010
[cited by applicant]
US 20130303395A1
· Lueking et al.
· 2013
[cited by applicant]
US 20170216244A1
· Tufro
· 2017
[cited by applicant]
WO WO2009145831A1
· 2009
[cited by examiner]
WO WO2019030461
· 2019
[cited by applicant]
WO WO2020037135
· 2020
[cited by applicant]
WO WO2021178863
· 2021
[cited by applicant]
Kalantari, Biomarkers in Medicine, 2017; 11: 781-797 (Year: 2017).
[cited by examiner]
Cattran et al., Kidney International (2017) 91, 566-574 (Year: 2017).
[cited by examiner]
Kuroda et al., Biochemical and Biophysical Research Communications (1999), 265, 79-86 (Year: 1999).
[cited by examiner]
Ahn et al., “Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1),” Nat. Genetics, Oct. 1, 1995, 11(2):137-143.
[cited by applicant]
Alarcón, “Multiethnic lupus cohorts: what have they taught US?,” Reumatol. Clinica, Dec. 23, 2010, 7(1):3-6.
[cited by applicant]
Almaani et al., “Update on Lupus Nephritis,” Clin. J. Am. Soc. Nephrology, Nov. 7, 2016, 12(5):825-835.
[cited by applicant]
Alto et al., “Semaphorins and their Signaling Mechanisms,” Methods Mol. Biology, Oct. 28, 2016, 1493:1-25.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, Sep. 1, 1997, 25(17):3389-3402.
[cited by applicant]
Anders, “Nephropathic autoantigens in the spectrum of lupus nephritis,” Nat. Rev. Nephrology, Jun. 13, 2019, 15(10):595-596.
[cited by applicant]
Aoki et al., “The reduction of heparan sulphate in the glomerular basement membrane does not augment urinary albumin excretion,” Nephrol. Dial. Transplantation, Jan. 1, 2018, 33(1):26-33.
[cited by applicant]
Bajema et al., “Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chron…
[cited by applicant]
Bech et al., “Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy,” Clin. J. Am. Soc. Nephrology, Aug. 7, 2014, 9(8):1386-1392.
[cited by applicant]
Beck Jr. et al., “Membranous nephropathy: from models to man,” J. Clin. Investigation, Jun. 2, 2014, 124(6):2307-2314.
[cited by applicant]
Beck Jr. et al., “M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” N. Engl. J. Medicine, Jul. 2, 2009, 361(1):11-21.
[cited by applicant]
Beck Jr. et al., “Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy,” J. Am. Soc. Nephrology, Jul. 22, 2011, 22(8):1543-1550.
[cited by applicant]
Bertelli et al., “Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease,” Front. Medicine, Jun. 11, 2018, 5:170, 13 pages.
[cited by applicant]
Bobart et al., “A Target Antigen-Based Approach to the Classification of Membranous Nephropathy,” Mayo Clin. Proceedings, Mar. 2021, 96(3):577-591.
[cited by applicant]
Borza, “Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation,” Matrix Biology, Sep. 6, 2016, 57-58:299-310.
[cited by applicant]
Brasch et al., “Thinking outside the cell: how cadherins drive adhesion,” Trends Cell Biology, May 1, 2012, 22(6):299-310.
[cited by applicant]
Busse et al., “Contribution of EXT1, EXT2, and EXTL3 to Heparan Sulfate Chain Elongation,” J. Biol. Chemistry, Nov. 9, 2007, 282(45):32802-32810.
[cited by applicant]
Busse et al., “In Vitro Polymerization of Heparan Sulfate Backbone by the EXT Proteins,” J. Biol. Chemistry, Oct. 17, 2003, 278(42):41333-41337.
[cited by applicant]
Busse-Wicher et al., “The extostosin family: Proteins with many functions,” Matrix Biology, Apr. 2014, 35:25-33.
[cited by applicant]
Chen et al., “Glomerular basement membrane and related glomerular disease,” Transl. Research, Oct. 2012, 160(4):291-297.
[cited by applicant]
Chen et al., “Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria,” Kidney International, Aug. 2008, 74(3):289-299.
[cited by applicant]
Chen et al., “Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices,” Kidney International, Dec. 1, 2010, 78(11):1088-1099.
[cited by applicant]
Cook et al., “Genetic Heterogeneity in Families with Hereditary Multiple Exostoses,” Am. J. Hum. Genetics, Jul. 1993, 53(1):71-79.
[cited by applicant]
Couser, “Primary Membranous Nephropathy,” Clin. J. Am. Soc. Nephrology, May 26, 2017, 12(6):983-997.
[cited by applicant]
De Vriese et al., “A Proposal for a Serology-Based Approach to Membranous Nephropathy,” J. Am. Soc. Nephrology, Oct. 24, 2016, 28(2):421-430.
[cited by applicant]
Du et al., “Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis,” Clin. Exp. Immunology, Feb. 17, 2017, 188(2):234-242.
[cited by applicant]
Duncan et al., “The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins,” J. Clin. Investigation, Aug. 2001, 108(4):511-516.
[cited by applicant]
Fervenza et al., “Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy,” N. Engl. J. Medicine, Jul. 4, 2019, 381(1):36-46.
[cited by applicant]
Frank et al., “Protocadherins,” Curr. Opin. Cell Biology, Oct. 2002, 14(5):557-562.
[cited by applicant]
Guan et al., “Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival,” Kidney International, May 2006, 69(9):1564-1569.
[cited by applicant]
Halbleib et al., “Cadherins in development: cell adhesion, sorting, and tissue morphogenesis,” Genes Development, Dec. 1, 2006, 20(23):3199-3214.
[cited by applicant]
Hanset et al., “Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study,” Am. J. Kidney Diseases, Jul. 12, 2020, 76(5):624-635.
[cited by applicant]
Hasebe et al., “Efficient Production and Characterization of Recombinant Human NELL1 Protein in Human Embryonic Kidney 293-F Cells,” Mol. Biotechnology, Aug. 5, 2011, 51(1):58-66.
[cited by applicant]
Hasebe et al., “The C-terminal region of NELL1 mediates osteoblastic cell adhesion through integrin a3ß1,” FEBS Letters, Jun. 20, 2012, 586(16):2500-2506.
[cited by applicant]
Herwig et al., “Thrombospondin Type 1 Domain-Containing 7A Localizes to the Slit Diaphragm and Stabilizes Membrane Dynamics of Fully Differentiated Podocytes,” J. Am. Soc. Nephrology, Apr. 10, 2019, 30(5):824-839.
[cited by applicant]
Hihara et al., “Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy,” PLoS One, Jun. 29, 2016, 11(6):e0158154, 12 pages.
[cited by applicant]
Huong et al., “Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center,” Medicine (Baltimore), May 1999, 78(3):148-166.
[cited by applicant]
Itakura et al., “Heparan sulfate is a clearance receptor for aberrant extracellular proteins,” J. Cell Biology, Mar. 2, 2020, 19(3):e201911126.
[cited by applicant]
Iwakura et al., “Primary Membranous Nephropathy with Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases,” Kidney Medicine, May 31, 2021, 3(4):669-673.
[cited by applicant]
Kanwar et al., “Contribution of Proteoglycans Towards the Integrated Functions of Renal Glomerular Capillaries: A Historical Perspective,” Am. J. Pathology, Jul. 2007, 171(1):9-13.
[cited by applicant]
Kuroda et al., “Biochemical Characterization and Expression Analysis of Neural Thrombospondin-1-like Proteins NELL1 and NELL2,” Biochem. Biophys. Res. Communications, Nov. 1999, 265(1):79-86.
[cited by applicant]
Lee et al., “Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis,” Lupus, Jan. 24, 2016, 25(7):727-734.
[cited by applicant]
Luce et al., “The neuronal EGF-related genes NELL1 and NELL2 are expressed in hemopoietic cells and developmentally regulated in the B lineage,” Gene, Apr. 29, 1999, 231(1-2):121-126.
[cited by applicant]
Makker et al., “Idiopathic membranous nephropathy: an autoimmune disease,” Semin. Nephrology, Jul. 2011, 31(4):333-340.
[cited by applicant]
Matshuhashi et al., “New gene, nel, encoding a M(r) 93 K protein with EGF-like repeats is strongly expressed in neural tissues of early stage chick embryos,” Dev. Dynamics, Jun. 1995, 203(2):212-222.
[cited by applicant]
McCarthy et al., “The Glomerular Basement Membrane as a Model System to Study the Bioactivity of Heparan Sulfate Glycosaminoglycans,” Microsc. Microanalysis, Feb. 2012, 18(1):3-21.
[cited by applicant]
McCormick et al., “The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate,” Proc. Natl. Acad. Sci. USA, Jan. 18, 2000, 9…
[cited by applicant]
Miner, “Glomerular basement membrane composition and the filtration barrier,” Pediatr. Nephrology, Feb. 15, 2011, 26(9):1413-1417.
[cited by applicant]
Miner, “Glomerular filtration: the charge debate charges ahead,” Kidney International, Aug. 2008, 74(3):259-261.
[cited by applicant]
Miner, “The glomerular basement membrane,” Exp. Cell Research, Mar. 5, 2012, 318(9):973-978.
[cited by applicant]
Morishita et al., “Protocadherin family: diversity, structure, and function,” Curr. Opin. Cell Biology, Oct. 23, 2007, 19(5):584-592.
[cited by applicant]
Nakamura et al., “Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma,” Cancer Science, Mar. 26, 2015, 106(5):656-664.
[cited by applicant]
Nesvizhskii et al., “A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry,” Anal. Chemistry, Jul. 15, 2003, 75(17):4646-4658.
[cited by applicant]
Neufeld et al., “The semaphorins and their receptors as modulators of tumor progression,” Drug Resist. Updates, Aug. 28, 2016, 29:1-12.
[cited by applicant]
Paulson et al., “Glycosyltransferases: Structure, localization, and control of cell type-specific glycosylation,” J. Biol. Chemistry, Oct. 15, 1989, 264(3):17615-17618.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020/051515, dated Mar. 15, 2022, 8 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/051515, dated Jan. 6, 2021, 11 pages.
[cited by applicant]
Pourcine et al., “Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years,” PLoS On…
[cited by applicant]
Pozdzik et al., “Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management,” BioMed Res. International, Jan. 8, 2018, 2018:6281054, 19 pages.
[cited by applicant]
ProteinAtlas.org [online], “NELL1—Kidney,” available on or before Feb. 9, 2021 via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20210209071800/https://www.proteinatlas.org/ENSG00000165973-NELL1/tiss…
[cited by applicant]
ProteinAtlas.org [online], “PCDH7—Kidney,” available on or before Jun. 26, 2015 via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20150626215650/https://www.proteinatlas.org/ENSG00000169851-PCDH7/tis…
[cited by applicant]
Raats et al., “Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuria,” Kidney International, Feb. 2000, 57(2):385-400.
[cited by applicant]
Ravindran et al., “In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes,” J. Am. Soc. Nephrology, Jan. 21, 2021, 32(3):695-706.
[cited by applicant]
Ravindran et al., “Proteomic Analysis of Complement Proteins in Membranous Nephropathy,” Kidney Int. Reports, Jan. 30, 2020, 5(5):618-626.
[cited by applicant]
Roberts et al., “Familial Nephropathy and Multiple Exostoses With Exostosin-1 (EXT1) Gene Mutation,” J. Am. Soc. Nephrology, Mar. 2008, 19(3):450-453.
[cited by applicant]
Ronco et al., “Pathogenesis of membranous nephropathy: recent advances and future challenges,” Nat. Rev. Nephrology, Feb. 28, 2012, 8(4):203-213.
[cited by applicant]
Ronco et al., “Pathophysiological advances in membranous nephropathy: time for a shift in patient's care,” Lancet, May 16, 2015, 385(9981):1983-1992.
[cited by applicant]
Rops et al., “Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis,” Kidney International, Apr. 23, 2014, 86(5):932-942.
[cited by applicant]
Rosini et al., “Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites,” Sci. Signaling, May 29, 2018, 11(532):eaar2566, 16 pages.
[cited by applicant]
Sano et al., “Protocadherins: a large family of cadherin-related molecules in central nervous system,” EMBO Journal, Jun. 1993, 12(6):2249-2256.
[cited by applicant]
Sethi et al., “Exostosin 1/Exostosin 2-Associated Membranous Nephropathy,” J. Am. Soc. Nephrology, May 6, 2019, 30(6):1123-1136.
[cited by applicant]
Sethi et al., “Mass Spectrometry Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis,” Clin. J. Am. Soc. Nephrology, Sep. 28, 2010, 5(12):2180-2187.
[cited by applicant]
Sethi et al., “Mass spectrometry based proteomics in the diagnosis of kidney disease,” Curr. Opin. Nephrol. Hypertension, May 2013, 22(3):273-280.
[cited by applicant]
Sethi et al., “Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy,” Kidney International, Oct. 10, 2019, 97(1):163-174.
[cited by applicant]
Sethi et al., “Protocadherin 7-Associated Membranous Nephropathy,” J. Am. Soc. Nephrology, Apr. 8, 2021, 32(5):1249-1261.
[cited by applicant]
Sethi et al., “Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients,” Kidney International, Nov. 1, 2020, 98(5):1253-1264.
[cited by applicant]
Stoddard et al., “Structure and function insights garnered from in silico modeling of the thrombospondin type-1 domain-containing 7A antigen,” Proteins, Dec. 21, 2018; 87(2):136-145.
[cited by applicant]
Stojan et al., “Epidemiology of systemic lupus erythematosus: an update,” Curr. Opin. Rheumatology, Mar. 2018, 30(2):144-150.
[cited by applicant]
Sugar et al., “N-sulfation of heparan sulfate is critical for syndecan-4-mediated podocyte cell-matrix interactions,” Am. J. Physiol. Renal Physiology, Mar. 2, 2016, 310(1):F1123-F1135.
[cited by applicant]
Sugar et al., “Podocyte-specific deletion of NDST1, a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities in podocyte organization in vivo,” Kidney International, Aug. 7, 2013, 85(2…
[cited by applicant]
Takamatsu et al., “Diverse roles for semaphorin-plexin signaling in the immune system,” Trends Immunology, Feb. 9, 2012, 33(3):127-135.
[cited by applicant]
Tapia et al., “Semaphorin3a disrupts podocyte foot processes causing acute proteinuria,” Kidney International, Dec. 12, 2007, 73(6):733-740.
[cited by applicant]
Ting et al., “Human NELL-1 Expressed in Unilateral Coronal Synostosis,” J. Bone Miner. Research, Jan. 1999, 14(1): 80-89.
[cited by applicant]
Tomas et al., “Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy,” J. Clin. Investigation, May 23, 2016, 126(7):2519-2532.
[cited by applicant]
Tomas et al., “Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy,” N. Engl. J. Medicine, Nov. 13, 2014, 371(24):2277-2287.
[cited by applicant]
UniProt Accession No. O60245, “Protocadherin-7,” dated Jun. 7, 2017, 5 pages.
[cited by applicant]
Van den Born et al., “Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases,” Kidney International, Feb. 1993, 43(2):454-463.
[cited by applicant]
Vrana et al., “Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens,” Blood, Oct. 1, 2009, 114(24):4957-4959.
[cited by applicant]
Watanabe et al., “Cloning and Characterization of Two Novel Human cDNAs (NELL1 and NELL2) Encoding Proteins with Six EGF-like Repeats,” Genomics, Dec. 15, 1996, 38(3):273-276.
[cited by applicant]
Yazdani et al., “The semaphorins,” Genome Biology, Mar. 30, 2006, 7(3):211, 14 pages.
[cited by applicant]
Zaghrini et al., “Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy,” Kidney International, Mar. 2019, 95(3):666-679.
[cited by applicant]
Zhang et al., “Craniosynostosis in transgenic mice overexpressing Nell-1,” J. Clin. Investigation, Sep. 2002, 110(6):861-870.
[cited by applicant]
Zhang et al., “Overexpression of Nell-1, a Craniosynostosis-Associated Gene, Induces Apoptosis in Osteoblasts During Craniofacial Development,” J. Bone Miner. Research, Dec. 2003, 18(12):2126-2134.
[cited by applicant]
Zhang et al., “The Role of NELL-1, a Growth Factor Associated with Craniosynostosis, in Promoting Bone Regeneration,” J. Dent. Research, Jul. 20, 2010, 89(9):865-878.
[cited by applicant]
U.S. Appl. No. 17/254,086, filed Dec. 18, 2020, M. Cristine Charlesworth, Published as U.S. Publication No. 2021/0270832.
[cited by applicant]